CRNO B Stock Overview
Cereno Scientific AB (publ), clinical stage biotechnology company, develops therapeutics to treat cardiovascular and rare diseases worldwide.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Cereno Scientific AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr4.04 |
52 Week High | kr5.45 |
52 Week Low | kr0.45 |
Beta | 0.018 |
1 Month Change | -7.64% |
3 Month Change | -14.13% |
1 Year Change | 418.77% |
3 Year Change | 99.80% |
5 Year Change | 53.46% |
Change since IPO | -35.42% |
Recent News & Updates
Shareholder Returns
CRNO B | SE Biotechs | SE Market | |
---|---|---|---|
7D | -6.2% | 3.6% | 1.1% |
1Y | 418.8% | -3.2% | 8.6% |
Return vs Industry: CRNO B exceeded the Swedish Biotechs industry which returned -3.2% over the past year.
Return vs Market: CRNO B exceeded the Swedish Market which returned 8.6% over the past year.
Price Volatility
CRNO B volatility | |
---|---|
CRNO B Average Weekly Movement | 8.1% |
Biotechs Industry Average Movement | 10.1% |
Market Average Movement | 6.2% |
10% most volatile stocks in SE Market | 13.5% |
10% least volatile stocks in SE Market | 3.6% |
Stable Share Price: CRNO B has not had significant price volatility in the past 3 months.
Volatility Over Time: CRNO B's weekly volatility has decreased from 15% to 8% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | 5 | Sten Sorensen | www.cerenoscientific.com |
Cereno Scientific AB (publ), clinical stage biotechnology company, develops therapeutics to treat cardiovascular and rare diseases worldwide. The company’s lead drug candidate is CS1, a product candidate that is in phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension, as well as a histone deacetylase (HDAC) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic, and antithrombotic properties. Its preclinical drug candidates comprise CS585 and CS014 that is in pre clinical stage for the treatment of cardiovascular diseases.
Cereno Scientific AB (publ) Fundamentals Summary
CRNO B fundamental statistics | |
---|---|
Market cap | kr1.13b |
Earnings (TTM) | -kr48.11m |
Revenue (TTM) | kr49.28m |
23.0x
P/S Ratio-23.6x
P/E RatioIs CRNO B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CRNO B income statement (TTM) | |
---|---|
Revenue | kr49.28m |
Cost of Revenue | kr0 |
Gross Profit | kr49.28m |
Other Expenses | kr97.38m |
Earnings | -kr48.11m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 23, 2024
Earnings per share (EPS) | -0.17 |
Gross Margin | 100.00% |
Net Profit Margin | -97.62% |
Debt/Equity Ratio | 21.0% |
How did CRNO B perform over the long term?
See historical performance and comparison